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ABSTRACT 
The IGF-1R is an important player in cancer development that maintains the malignant 
phenotype by inducing cell proliferation, survival, transformation, motility and invasiveness. 
Activation of IGF-R results in its Mdm2-dependent ubiquitination and degradation followed 
by MAPK signaling. IGF-1R ubiquitination by Mdm2 is mediated by scaffolding protein β-
arrestin 1. The tumor suppressor p53 pathway is activated in damaged cells causing growth 
arrest and if necessary, apoptosis and senescence. In normal conditions p53 is inactivated by 
Mdm2. Activation of extracellular pro-survival signaling has been shown to inhibit p53 
activity through β-arrestin 1. Thus the same Mdm2/β-arrestin 1 system regulates two 
important pathways involved in cancer. 
The aim of this thesis was to investigate in detail the IGF-1R/β-arrestin/Mdm2/p53 axis and 
explore the potential use of its components as anti-cancer therapeutic targets. 
In Paper I we analysed the molecular interplay between p53 and IGF-1R through Mdm2. We 
tested the effect of p53/Mdm2 disruption on IGF-1R using a panel of melanoma cells and the 
p53-rectivator Nutlin-3. Disruption of the p53/Mdm2 interaction by Nutlin-3 increased the 
IGF-1R/Mdm2 interaction, followed by IGF-1R degradation and MAPK activation. This 
resulted in reduced cell proliferation and invasion and had a two-step effect on cell migration, 
demonstrating that modulation of the p53/Mdm2/IGF-1R axis is a potential anti-cancer 
therapeutic strategy. 
In paper II we focused on the role of β-arrestin isoforms in the p53/Mdm2/IGF-1R axis. By 
modulating levels of β-arrestin 1 or 2 we identified opposing roles of isoforms on IGF-1R 
degradation, signaling and p53 pathway. We revealed a higher affinity of ligand-free IGF-1R 
for β-arrestin 2, and ligand occupied receptor - for β-arrestin 1. Antagonism between 
isoforms was also observed on biological effects with β-arrestin 2 causing cell cycle arrest 
and inhibiting IGF-1 response and cell viability, and β-arrestin 1 acting in the opposite 
direction. Thus we identified the β-arrestin 1/2 system as a second potential drug target within 
the p53/Mdm2/IGF-1R axis. 
In paper III we studied the possibility of co-targeting the p53/Mdm2/IGF-1R and the MAPK 
pathway in melanoma cell lines. We combined MEK inhibitors with 1) balanced IGF-1R 
inhibition by siRNA; 2) biased IGF-1R inhibition by Nutlin-3, inducing transient MAPK; and 
3) biased IGF-1R inhibition by antibody CP, inducing prolonged MAPK. We identified 
strong synergy between Nutlin-3 and MEK inhibitors. This combination of specific biased 
IGF-1R inhibition with MEK inhibitors is the first rational anti-cancer strategy identified in 
this thesis. 
In paper IV we investigated the possibility of co-targeting the β-arrestin system with the 
DNA-damage inducing drug dacarbazine. By modulating the level of β-arrestin isoforms in 
melanoma cell lines we demonstrated that both β-arrestin 1 inhibition and β-arrestin 2 
overexpression synergize with dacarbazine. This study revealed the second rational anti-
cancer strategy of this project. 
To sum up, our findings demonstrate that the p53/Mdm2/IGF-1R axis is a potential target for 
anti-cancer therapy. However, optimal effects can be achieved only through accurate 
modulation of multiple pathways regulated by the axis.  
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1. INTRODUCTION 
1.1. Cancer and its hallmarks 
Cancer is one of the leading causes of morbidity worldwide, accounting for approximately 
13% of all deaths each year [1]. The number of diagnosed cases of cancer increases every 
year, particularly in countries with an ageing population [1]. More than 30% of cancer deaths 
could be avoided by better control of risk factors, early diagnosis and treatment [2-5]. 
Cancer development is a complex and multi-step process during which initially normal cells 
acquire various capabilities to grow, survive and disseminate [6]. These capabilities include six 
core and two emerging hallmarks of cancer [6]. 
Core hallmarks of cancer include: 
(i) Sustaining proliferative signaling: In normal cells entry into a new cycle is under 
the control of growth factors, such as epidermal growth factor (EGF), vascular 
endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF-1) etc [7]. In 
cancer cells these pathways are dysregulated by the increased production of growth 
factors or receptors as well as by structural changes of the receptor and/or 
components of its downstream signaling [8-10]. 
(ii) Evading growth suppressors: Cancer cells also have to bypass multiple tumor 
suppressor pathways that limit proliferation of normal cells [11]. Tumor suppressor 
proteins such as retinoblastoma protein (pRb) and p53 are able to induce cell cycle 
arrest or apoptosis in response to various extra- and intracellular signals [12, 13]. In 
cancer cells these proteins can be lost or mutated and gain new carcinogenic 
functions [14, 15]. 
(iii) Resisting cell death: Normal cells in stressed conditions undergo cell death via 
apoptosis, autophagy and necrosis through the p53 pathway [16, 17]. Tumor cells 
can avoid apoptosis through increased proliferative signaling or modulation of anti-
apoptotic and pro-apoptotic factors [18]. However, tumor cells can also induce cell 
death in order to recruit carcinogenic inflammatory agents [19, 20]. 
(iv) Enabling replicative immortality: Chromosomal DNA of cells is protected by 
telomeres that shorten in time increasing possibilities of chromosomal fusions, 
leading to cell senescence and apoptosis [21]. Cancer cells are able to conserve 
telomere length, by increased production of the protective enzyme telomerase [22-
25]. 
(v) Inducing angiogenesis: In normal adult tissues, angiogenesis is activated 
transiently in accordance with physiological needs [26]. In cancer cells it is 
constantly activated by dysregulation of pro-angiogenic growth factors, such as 
VEGF, fibroblast growth factor (FGF) and thrombospondin 1 (TSP1), sustaining a 
tumor’s nutrient supply and providing a transport system for metastasizing cells 
[27-29]. Moreover, the angiogenic switch is also facilitated by infiltration of tumor 
by cells of the immune system [30, 31]. 
(vi) Activating invasion and metastasis: Normally cells are attached to each other as 
well as to the extracellular matrix [32]. Cancer cells can lose these abilities by 
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expression of embryonic factors enabling epithelial-mesenchymal transition and 
dysregulation of adhesion factors enabling motility and invasiveness [33, 34]. 
Immune cells surrounding the tumor can contribute by activating proteolytic 
enzymes or growth factors [35, 36] 
Emerging hallmarks of cancer include: 
(vii) Reprogramming energy metabolism: Normal cells undergo two stages of  
glycose processing and switch to the single stage glycolysis in anaerobic conditions 
[37]. Cancer cells can switch to the single stage glycolysis even in the presence of 
the oxygen thus possibly redirecting glycolytic intermediates towards neighboring 
and new cells [38-40]. This switch can be induced by activation of oncogenes or 
alteration of tumor suppressors [41, 42]. 
(viii) Evading immune destruction: Cells are constantly scanned by immune cells and 
eliminated in case of aberrancy [43, 44]. Cancer cells acquire the ability to hide and 
evade immune system by producing immunosupressive factors or recruiting 
immunosupressive inflammatory cells [45-48]. 
Two enabling characteristics of cancer are required for the acquisition of hallmark of cancer by 
normal cells [6, 49]. These characteristics include: 
(i) Genome instability and mutation: Various alterations in the cellular genome 
enable acquisition of the hallmarks of cancer [50]. Mutations of certain genes 
involved in guarding DNA, such as p53, facilitate further aquisition of carcinogenic 
mutations and survival of transformed cells [25, 51]. 
(ii) Tumor promoting inflammation: Inflammation and recruitment of the immune 
cells also helps to acquire hallmarks of cancer by supplying cells with various 
survival, growth and proangiogenic factors as wells as mutagenic oxygen species 
[20, 52, 53]. 
In addition, the tumor microenvironment can exploit neighboring normal cells, creating 
beneficial surroundings for tumor growth thus acting as a contributing factor to cancer [35, 54, 
55]. 
Various reconsideration of classification were proposed such as including such characteristics 
as genome instability and stress phenotypes as a separate emerging hallmarks of cancer [56]. 
1.2. Growth factors and tumor suppressors 
The balance between two important biological pathways are involved in most if not all 
hallmarks of cancer: growth factor receptor signaling and tumor suppressor pathways [57-61]. 
Growth factors bind to their receptors, activating signaling pathways that regulate 
proliferation, survival and differentiation of normal cells [62-65]. These pathways become 
potentially oncogenic when any of their components are hyper-activated due to various genetic 
or epigenetic alterations [8, 66, 67]. 
The anti-oncogenic tumor suppressors negatively regulate cell proliferation and normally 
induce death of incompatible cells [61]. This pathway becomes oncogenic when its components 
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lose their activity as a result of various mutations [61, 68]. Typically both copies of tumor 
suppressor genes must be mutated for malignant transformation of cell [69]. 
1.3. Growth factor receptors and cancer 
Most of the growth factor receptors belong to the family of receptor tyrosine kinases (RTKs) 
[10, 70]. The RTK family includes 58 receptors with related structure [71, 72]. Most RTKs are 
monomers with extracellular, transmembranous and intracellular domains with protein kinase 
activity [10, 73]. Ligand binding to the extracellular domain induces RTK dimerization [10, 71, 
73]. Dimerized monomers cross-phosphorylate tyrosine resides in the intracellular domains of 
each other, increasing the receptor-kinase activity and creating docking sites for the proteins 
involved in signal transduction [73, 74]. Various downstream molecules containing SH2 or 
PTB domains are directly or indirectly recruited to these phosphotyrosines, transmitting 
information to the cell’s nucleus and other regulatory organelles [71, 75, 76]. The most well 
studied examples of activation cascades downstream of RTKs are the mitogen-activated 
protein kinase (MAPK) and phosphatidylinositol 3-kinases (PI3Ks) pathways [77]. 
Increased production or hyperactivation of different component of RTK signaling contributes 
to cancer development [9, 10, 36, 78]. Some of the RTKs involved in cancer development 
include epidermal growth factor receptors (EGFR), vascular endothelial growth factor receptors 
(VEGFR), platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptor 
(FGFR) and insulin-like growth factor receptor IGF-1R [9, 10]. 
The EGFRs regulate proliferation, differentiation and migration of normal cells [79]. Increased 
production of ligands and/or receptors as well as mutations of the tyrosine kinase domain are 
found in diverse types of cancers and associated with poor prognosis [10, 80]. 
VEGFR is mainly expressed on endothelial cells and plays a key role in vasculo-, angio- and 
lymphoangiogenesis [81, 82]. VEGFRs contribute to carcinogenesis by formation of blood 
and lymph vessels in the tumor and its microenvironment [83]. Up-regulation of VEGFR is 
found in various types of malignancies [84]. 
PDGFR normally controls proliferation and migration of mesenchymal cells [85]. Autocrine 
signaling maintained by this receptor has been demonstrated in many tumors [86, 87].  
FGFRs are involved in organ development during embryogenesis as well as in tissue 
homeostasis, proliferation, inflammation and angiogenesis in adults [28, 65]. Gene 
amplification, chromosomal translocations, gene fusions and missense mutations of FGFRs are 
found in various types of cancers [28].  
IGF-1R system 
The IGF-1R system consists of two ligands (IGF-1 and IGF-2), three cell membrane receptors 
(IGF-1R, IGF-2R and IR) and seven binding proteins (IGFBP-1-7) [88]. IGF-1 and IGF-2 
ligands share 62% homology and are mainly secreted by hepatocytes after growth hormone 
stimulation [89]. IGF-1 ligand in turn inhibits the secretion of growth hormone by the pituitary 
glands [90]. Around 90% of circulating IGF is inactive through binding to IGFBPs [91, 92]. 
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IGF-1R structure 
IGF-1R belongs to the family of insulin receptors with a structure more complex than most 
RTKs [73, 74, 93]. The IGF-1R gene encodes for a single precursor that is cleaved generating 
two α and two β subunits [94]. Distinct subunits are heterodimerized after glycosylation further 
forming a tetramer stabilized by disulfide bonds (β-α-α-β) [94, 95]. α-subunits are entirely 
extracellular and contain an IGF-1 binding site, while β subunits span the membrane and 
consist of extracellular, transmembranous and intracellular parts [93, 95]. The intracellular part 
of the β-subunit is divided into a juxtamembrane domain, tyrosine kinase domain and C-
terminal domain [96]. 
IGF-1R function 
In an inactive state the activation loop (A-loop) of the intracellular tyrosine kinase domain of 
IGF-1R behaves as a pseudo-substrate, blocking both substrate and ATP-binding sites of the 
receptor [97]. IGF-1 and IGF-2 binding to the α-subunit of IGF-1R causes conformational 
changes in the receptor followed by autophosphorylation of tyrosines at positions 1131, 1135 
and 1136 of the A-loop by their dimeric subunit partner [71, 97]. Initial phosphorylation of 
Y1135 induces a stable structure followed by phosphorylation Y1131 and Y1136 [97, 98]. 
These conformational changes of the A-loop allow ATP binding and activation of several other 
tyrosine residues including Y950 at juxtamembrane domain of the receptor [97, 98]. Activated 
Y950 serves as a docking site for insulin receptor substrate 1 (IRS1) and Src homology 2-
containing protein (Shc) that link the activated receptor to downstream pathways activating 
tyrosine kinase signaling (TK signaling) of IGF-1R [97, 98]. (Figure 1) 
IRS-1 binds to the regulatory p85 subunit of PI3Ks, which allows the activation of its catalytic 
p110 subunits [99]. Activated PI3K phosphorylates the phosphatidyl-inositol bisphosphate 
(PIP2) and generates phosphatidyl-inositol trisphosphate (PIP3), which interacts with serine 
threonine kinase Akt [95, 99]. This interaction causes translocation of the complex to the inner 
membrane and activation of Akt by 3-phosphoinositide-dependent protein kinase 1 (PDK1) 
[100, 101]. Activated Akt induces numerous cellular processes including cell cycle progression, 
cell migration and anti-apoptosis signals [99, 102]. (Figure 1) 
Shc or IRS-1 also recruits the growth factor receptor-binding protein 2 (Grb2) that interacts 
with son of sevenless (SOS), a plasma membrane guanine exchange factor (GEF) for Ras 
protein [103, 104]. Activated Ras interacts with Raf, which phosphorylates and activates 
MAPK/ERK kinase (MEK), which in turn phosphorylates and activates extracellular signal-
regulated kinases (ERKs) [88, 105]. This signaling cascade is called MAPK pathway [106]. 
Activated ERKs phosphorylate a number of cytosolic substrates and translocate to the nucleus, 
activating various transcription factors that regulate cellular proliferation, differentiation and 
transformation [107, 108]. (Figure 1) 
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Biological effects 
The IGF-1R axis has been shown to play important roles in neonatal and pubertal development 
by inducing cell proliferation, differentiation and inhibiting apoptosis [109]. It is also important 
for maintenance of normal cell growth, metabolism and adhesion [110, 111]. Disruption of 
IGF-1 and IGF-2 genes result in dwarfism, decreased viability and significant weight loss in 
mice, that survive, while disruption of the IGF-1R gene results in a more severe dwarfism and 
death shortly after birth [112]. Double disruption of both IGF-1 and IGF-1R genes results in a 
phenotype similar to that seen in the disruption of IGF-1R, while double disruption of IGF-2 
with IGF-1R and IGF-1 with IGF-2R genes results in a further increase in dwarfism [112]. 
The first report of IGF-1R involvement in cancer was by Pollak et al. in 1987 [113]. Since then 
a growing body of evidence indicates critical roles for the IGF-1R axis in cancer [111]. Various 
components of IGF-1R axis are elevated during cancer development [111, 114, 115]. Increased 
level of IGF-1 and IGF-2 ligands and IGF-1R were found in various types of cancer [116-118].  
Production of IGF-1 can increase via endocrine, paracrine and autocrine regulation by cancer 
cells [119-121]. Numerous studies also identified high levels of IGF-1R expression in tumors 
due to mutations causing IGF-1R gene amplification or other unknown mechanisms [122]. In 
addition, other components of the IGF-1R system, such as IRSs and IGFBPs can be 
deregulated in different tumors [123-127]. However, several studies indicate inverse correlation 
with level of IGF-1R and cancer progression [128-131]. For instance, it was reported that the 
level of IGF-1R is decreased particularly at late stage of prostate cancer development [128-
131]. The precise reason behind this controversy remains to be elucidated. 
Up-regulation of components of the IGF-1R axis induces tumor development through increased 
p110 p85 
Fig 1 
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Figure 1. Schematic illustration of signaling cascades downstream of IGF-1R: Activated 
IGF-1R recruits 1) Shc inducing MAPK pathway, which leads to the transcriptional 
activation of genes involved in cell proliferation, transformation and differentiation; and 2) 
IRS1-4 inducing PI3K pathway, involved in protein synthesis through mTOR and anti-
apoptosis through inhibition of BAD.  
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cell proliferation, anti-apoptosis, transformation, migration and invasion [111, 114, 115]. IGF-
1R induces cell proliferation through the activation of the MAPK pathway downstream 
receptor substrates IRS-1 and Shc [132-134]. However, the same pathways are responsible for 
IGF-1R induced cell differentiation [135]. It has been shown that one of the factors that control 
the switch between IGF-1R induced proliferation and differentiation is the balance between 
substrates: IRS-1 predominance induces proliferation and malignant transformation, while Shc 
predominance induces differentiation [135]. 
Cells lacking IGF-1R are unable to be transformed by several oncogenes including SV40 T 
antigen and/or activated Ha-Ras, c-Src, EGFR and bovine papillomavirus E5 [136]. On the 
other hand v-Src and GTPase deficient Gα13 are able to sustain transformation in the absence 
of IGF-1R [137, 138]. One of the explanations is the ability of v-Src and Gα13 to bypass IGF-
1R requirement by tyrosine phosphorylating the IGF-1R substrate IRS-1, directly involved in 
transformation, however the exact mechanism of IGF-1R induced cell transformation remains 
to be investigated [139]. 
IGF-1R protects against apoptosis via the activation of PI3K, MAPK and 14.3.3/Raf-1/Nedd4 
pathways that phosphorylates BAD and inhibits its heterodimerization with anti-apoptotic 
proteins Bcl-2 and Bcl-Xl, which in turn inhibits pro-apoptotic proteins Bak and Bax and 
cytochrome C release [105, 140-142]. This prevents caspase activation and sustains 
mitochondrial integrity [105, 108, 140-142]. 
It has been shown that proliferative and anti-apototic effects of IGF-1R require the tyrosine 
kinase domain with either juxtamembrane or C-terminal domains, while cell differentiation and 
transformation require all three domains of the receptor [137, 143, 144]. 
The IGF-1R system regulates cell motility and invasiveness through PI3K mediated up-
regulation of p125 focal adhesion kinase (p125Fak), p130 Crk-associated substrate (p130Cas), 
paxillin and matrix metalloproteinases 2 and 9 (MMP-2 and 9) [145-153].  However, dual 
effects of IGF-1R on MMP production have been reported – stimulatory in the presence of an 
activated PI3K pathway and inhibitory in conditions with predominantly activated MAPK 
pathway [154]. Another way of increasing tumor metastasis is IGF-1 and IGF-2 induced 
angiogenesis through activation of hypoxia-inducible factor 1α (HIF-1α) and transactivation of 
other growth factors such as VEGF [155-157]. It was also demonstrated that IGF-1 can activate 
urokinase plasminogen activator (uPA)/uPA receptor system (uPAR) thus leading to tumor 
invasion [158]. Thus the IGF-1R system can regulate tumor invasion and metastasis at multiple 
levels [159, 160]. 
IGF-1R as an RTK/GPCR hybrid 
It has been increasingly recognized during the last decade that despite being a prototypical 
RTK, IGF-1R also shares all functional characteristics of G-protein-coupled receptors (GPCRs) 
[88]. IGF-1R was shown to utilize G-protein signaling, G protein receptor kinase (GRK)/β-
arrestin induced desensitization, receptor ubiquitination, trafficking and signaling as well as the 
concept of biased signaling of GPCRs [88]. 
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GPCRs 
GPCRs are the largest family of cell surface receptors, and share a similar seven-
transmembranous structure and mechanism of activation [161]. In basal conditions, a GPCR is 
located adjacent to heterotrimeric G proteins that consist of Gα-GDP, Gβ and Gγ subunits 
[162]. A ligand bound receptor undergoes conformational changes to activate its GEF function 
followed by association with the Gα-GDP subunit and exchange of its GDP to GTP [163, 164]. 
This leads to dissociation of Gα-GTP from the Gβγ dimer, its interaction with second 
messengers and activation of the receptor signaling [163]. Intrinsic GTPase activity of Gα-
subunit causes hydrolysis of GTP to GDP returning the subunit to its inactive state [165]. Gβγ 
triggers activation of GRKs, which phosphorylate the C-terminus of the receptor, recruiting β-
arrestins [166]. β-arrestin binding uncouples the receptor from the Gα subunit leading to 
degradation of second messengers and further signal cessation [167]. However, there are also 
alternative models suggesting that certain GPCR/G protein complexes pre-exist and persist, but 
rearrange after receptor activation [168-174]. 
GPCRs: G protein 
According to the classical model, when the ligand binds to a GPCR triggering dissociation of 
activated Gα-GTP from Gβγ subunits, both partners further activate their specific effector 
enzymes [175, 176]. There are four different G proteins based on their distinct α subunit: 
Gαsβγ, Gαi/oβγ, Gαq/11βγ and Gα12/13βγ [177, 178]. G protein specificity of GPCRs plays an 
important role in determination of the proper signaling downstream of the receptor [179-181]. 
Table 1 illustrates the involvement of different G-protein families in various GPCRs. 
 
Gα family Signal transduction GPCRs References 
Gαs family Stimulation of adenylyl cyclase β1AR, β2AR, V2R [177, 178, 182] 
Gαi family 
Inhibition of adenylyl cyclase and 
regulation of ion channels and 
activation of phosphodiesterase 6 
α2AR, β1AR, 
β2AR, PAR1 
[177, 178, 183, 
184] 
Gαq family Activation of phospholipase C 
α1AR, AT1R, 
PAR1, PAR2 
[177, 185-187] 
Gα12/13 family Activation of Rho GTPases PAR1, PAR2 [177, 178, 188] 
 
Some GPCRs interact with several classes of Gα proteins activating different signaling 
pathways [189, 190]. 
Additionally Gβγ utilizes five different Gβ subtypes and eleven Gγ subtypes that also 
regulate effectors such as adenylyl cyclase, ion channels, PI3K, phospholipase C [175, 191]. 
Dissociated Gβγ is also isoprenylated interacting with the plasma membrane and recruiting 
GRKs close to the activated receptor [192, 193]. 
Table 1. G-protein families, their signal transduction pathways and examples of coupled 
GPCRs. 
 8 
GPCRs: GRKs 
GRKs are receptor associated serine/threonine kinases that phosphorylate serine or threonine 
residues within the C-terminus of the activated GPCRs, thus reducing G protein mediated 
signaling [194]. There are seven GRK isoforms divided into three groups: the visual GRK1 and 
GRK7 subfamily, the GRK2 and GRK3 subfamily, and the GRK4, GRK5 and GRK6 
subfamily [195-197]. Visual GRKs are expressed only in the retina, GRK4 is expressed only in 
the testis while all the other GRKs are expressed ubiquitously [195]. GRK isoforms differently 
phosphorylate GPCRs leading to distinct types of receptor signaling, trafficking and biological 
outcomes [195-197]. The term GRK phosphorylation “barcode” is used to describe different 
GRK-dependent phosphorylation patterns of GPCRs [195]. The fact that GRK2 KO mice (-/-) 
die at the embryonic stage while GRK3 and GRK5 KO mice are viable confirms non-identical 
roles of GRK isoforms [198, 199]. It has been shown that GRK2 and 3 play major roles in 
desensitization of β-2 adrenergic receptor (β2AR) and angiotensin II type 1 receptor (AT1R), 
while GRK 5 and 6 are involved in their β-arrestin mediated signaling [200-204]. However, it 
was also demonstrated that GRK 2 predominantly mediates β2AR desensitization in cardiac 
tissue, while in uterine smooth muscle this function carried out by GRK 6 [205]. Thus 
GPCR/GRK interaction differs depending on class of the receptor, biological function and 
organ specificity [195-197]. 
GPCRs: β-arrestins   
Arrestins were firstly discovered as proteins that together with GRKs attenuate receptor 
signaling, a process called receptor desensitization [199]. There are four different arrestin 
isoforms: arrestins 1 and 4 regulate photoreceptors and are expressed predominantly in the 
retina, and arrestin 2 and 3 (called β-arrestin 1 and 2) regulate most GPCRs and are expressed 
ubiquitously [206]. Both β-arrestins are elongated molecules with two domains: N-domain and 
C-domain with a connecting C-terminal tail [206]. A polar core between the two domains is 
mainly responsible for β-arrestin binding to the phosphorylated receptor, though both N- and C-
domain contain receptor-binding elements [207-209]. β-arrestin isoforms have identical N-
terminus and different C-terminus, which promotes differences in receptor binding [210]. Both 
β-arrestin 1 KO (βarr1-/-) and β-arrestin 2 KO (βarr2-/-) mice survive while double KO mice 
(βarr1-/- and βarr2-/-) show neonatal lethality, confirming that at least one isoform is important 
for the vital function of β-arrestins during development [211]. Thus β-arrestins have distinct as 
well as overlapping biological functions and are able to replace each other in specific 
conditions [211].  
Although firstly discovered as proteins mediating receptor desensitization, β-arrestins are now 
recognized as mediators of two other important functions of the receptor: i) in targeting a 
receptor to endocytic machinery followed by its internalization and degradation or recycling 
called receptor trafficking; and ii) activation of alternative G-protein independent receptor 
signaling called β-arrestin (or β-arrestin-dependent) signaling [210]. 
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GPCR desensitization 
β-arrestins are presumably “phosphosensors” that bind to activated and phosphorylated 
receptors and induce post-translational changes to the receptor [212]. The altered receptor 
uncouples an activated Gα subunit, which leads to signal cessation and receptor endocytosis 
[212]. In addition to that, β-arrestins can recruit phosphodiesterase (PDE) enzymes and induce 
degradation of Gα-GTP activated second messengers [167]. However, it was demonstrated 
recently that certain receptors can couple to G proteins even after β-arrestin binding resulting in 
formation of the receptor/β-arrestin/G protein complex, giving rise to sustained G protein 
signaling [172, 173].  
β-arrestin 1 KO mice (-/-) survive but exhibit decreased β2AR signal cessation, suggesting that 
β-arrestin 1 plays an important role in β2AR desensitization [213]. However, it was shown that 
in vitro silencing of β-arrestin 2 affects β2AR desensitization even more than silencing of β-
arrestin 1 [214]. Testing β2AR signaling in mouse embryo fibroblasts (MEFs) lacking either or 
both β-arrestins indicated that the role of isoforms in β2AR desensitization is interchangeable 
[199]. It has been identified that both β-arrestin isoforms are equally involved in desensitization 
of AT1R [215]. Another example is protease-activated receptors 1 and 2 (PAR1, PAR2) 
desensitized via both β-arrestins, with β-arrestin 1 initiating the process and thus playing 
predominant role [216-223]. 
GPCR trafficking 
Receptor trafficking is another key process that controls the duration of its signaling [224-226]. 
β-arrestins bound to the phosphorylated receptor are able to interact with elements of the 
endocytic machinery such as clathrin and AP2 resulting in receptor internalization [224, 227, 
228]. An internalized receptor is dephosphorylated and either recycled back to the cell surface 
or degraded by proteasome and lysosomes depending on the strength of the receptor/β-arrestin 
binding [224-229]. Two classes of GPCRs have been identified based on the strength of this 
interaction [219, 227]. Class A receptors preferentially and transiently bind to β-arrestin 2 
followed by fast dissociation of the complex and internalization of the receptor through 
clathrin-coated pits [219, 227]. This class of receptor includes β2AR, α1 adrenergic (α1AR), µ 
opioid (MOR) and dopamine 1A (D1AR) receptors [219, 227]. Class B receptors stably bind to 
both β-arrestin isoforms followed by internalization of the receptor together with β-arrestins 
[219, 227]. This group of receptors includes AT1R, neurotensin 1 (N1) and vasopressin (V2) 
receptors [219, 227]. Class A receptors preferentially induce receptor recycling while class B 
receptors induce receptor degradation [219, 227]. The switch of C-terminal tail of the receptor 
changes their class affinity, indicating that the C-terminus determines class specificity [219]. 
GPCRs and β-arrestin signaling 
The third consequence of β-arrestin binding to GPCRs is activation of G-protein independent β-
arrestin signaling through interaction of β-arrestins with a variety of cellular molecules [210]. 
Receptor bound β-arrestins can scaffold multiple signaling molecules thus transducing signals 
to the MAPK, PI3K, NF-κB, p53 and other pathways [210, 224, 230]. This results in a variety 
of biological outcomes such as cell proliferation, anti-apoptosis, migration and invasion [230]. 
Interestingly the same pathway activated through G-protein or β-arrestin signaling can lead to 
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distinct biological outcomes [231]. For instance, β-arrestin activated ERK1/2 is mostly 
localized in the cytoplasm and interacts with cytosolic substrates, whereas G-protein activated 
ERK1/2 moves to the nucleus and acts as a transcription factor [232, 233]. Thus it is not 
surprising that β-arrestin activated ERK1/2 regulates proteins involved in cell motility and 
chemotaxis, rather than transcription activity and subsequent cell proliferation [234]. 
Receptor class specificity also influences the length of β-arrestin induced signaling: transient 
interaction of Class A receptors with β-arrestin 2 activates short β-arrestin signaling, while 
stable interaction of Class B receptors with both β-arrestins leads to a stable β-arrestin signaling 
[224]. However, there are exceptions from the classical pattern of β-arrestin mediated receptor 
trafficking and signaling. It has been demonstrated that PAR2 receptor is degraded faster 
through interaction with β-arrestin 1, while β-arrestin 2/PAR2 interaction leads to more stable 
association and signaling [223]. 
In addition regardless of the class specificity β-arrestin isoforms can play co-dependent or 
reciprocal role in regulation of the β-arrestin induced signaling [218, 224]. Furthermore 
reciprocal regulation can appear as a positive input of β-arrestin 1 and negative by β-arrestin 2 
or vice versa [218]. 
Distinct roles of β-arrestin isoforms in receptor desensitization, endocytosis and signaling are 
partially explained by recently identified specific conformations of β-arrestin/GPCR 
interaction. It has been shown that interaction of β-arrestins with the C-terminus of GPCRs 
mediate receptor internalization and signaling, while additional interaction of β-arrestins with 
the receptor transmembrane core mediates desensitization [172, 173]. However, β-
arrestins/GPCR interactions that discriminate the roles of isoforms in receptor endocytosis from 
signaling remain to be investigated. 
Other functions of β-arrestins 
It is important to mention that β-arrestin isoforms also specifically regulate functions other than 
desensitization, trafficking and β-arrestin signaling of the receptor [235, 236]. β-arrestin 1 can 
move to the nucleus in response to receptor activation, enhancing histone acetylation and gene 
transcription, while β-arrestin 2 is involved in nuclear export of Mdm2 and JNK3 kinases [237-
240]. It has been suggested that these functions are controlled by non-identical C-terminal 
regions of the isoforms [237-240].  
Posttranslational modifications of β-arrestins 
Various posttranslational modifications of β-arrestins such as ubiquitination and 
phosphorylation regulate GPCR functions [227, 241]. Ubiquitination pattern of β-arrestins 
correlates with GPCR class specificity: transient β-arrestin ubiquitination with class A and 
persistent β-arrestin ubiquitination with class B [227, 242]. The state of β-arrestin 
phosphorylation defines receptor endocytosis for example, dephosphorylation of serine residue 
412 of β-arrestin 1 increases its affinity for clathrins [243-245]. Oligomerization state also 
controls β-arrestins activity [246]. β-arrestin 1 or 2 monomers are ubiquitinated by Mdm2 and 
involved in receptor desensitization as well as transcriptional activity of β-arrestin 1 [246, 247].  
However, β-arrestin 2 oligomers are involved in the nuclear export of Mdm2 [246-248]. 
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Different models of GPCR regulation by β-arrestin 1 and 2 isoforms 
The β2AR belongs to the class A receptors and its C-terminus phosphorylation leads to the 
transient binding of β-arrestin 2 followed by receptor internalization and recycling [219]. 
However, both β-arrestin isoforms can induce arrestin dependent ERK activation of β2AR 
[204]. On the other hand, AT1R belongs to class B receptors and its C-tail phosphorylation 
recruits both β-arrestins that stably bind to the receptor [219]. However, the β-arrestin isoforms 
play a reciprocal role in activation of signaling: β-arrestin 1 induces, while β-arrestin 2 inhibits 
the arrestin signaling of AT1R [217]. Distinct roles of β-arrestin isoforms in endocytosis and 
signaling of different GPCRs are shown in Table 2. 
Simplified models of G-protein, GRK and β-arrestin isoform interactions with the most 
extensively studied β2AR and AT1R GPCRs are illustrated in Figure 2.  
 
 
GPCR Desensitization Traffiking Signaling References 
β2AR β-arr2>β-arr1 β-arr2>β-arr1 β-arr1↑/β-arr2↑ [204, 218, 219] 
AT1R β-arr1/β-arr2 β-arr1/β-arr2 β-arr1↓/β-arr2↑ [218, 219, 232] 
PAR1 β-arr1>β-arr2 Not essential β-arr1↑/β-arr2↓ [216-220] 
PAR2 β-arr1>β-arr2 β-arr1/β-arr2 β-arr1↑/β-arr2↑ [218, 219, 221-223] 
B2AR	
signaling	
Gαs P 
P 
Barr	
signaling	
GRK2 Gβγ 
P 
AT1R	
signaling	
Barr	
signaling	
GRK6 
Gβγ 
PAR1	(no	class)	barr1only	desens!	(not	endocyt..)	Par	pERK	is	codep-barr1up,	barr2	
inhibits	kak	igf-1r	
βarr2
βarr1
βarr2
βarr1
Gαq P 
GRK2 
a b 
GRK6 
Table 2. Role of β-arrestin isoforms in GPCRs desensitization, endocytosis and signaling. 
↑- stimulatory role; ↓- inhibitory role; > - more potent regulation. 
Figure 2. Schematic illustration of the roles of G proteins, GRKs and β-arrestins in β2AR and 
AT1R signaling. a) β2AR activation is followed by interaction with Gαsβγ, phosphorylation by 
GRK2/6 and β-arrestin1/2 binding; b) AT1R activation followed by interaction with Gαqβγ, 
phosphorylation by GRK2/6 and β-arrestin1/2 binding. Distinct effects of β-arrestins on 
desensitization, downregulation and signaling are shown with red lines. Arrowed lines indicate 
stimulatory and blunted lines - inhibitory effects. Transparent lines indicate weaker effects. 
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GPCRs: biased signaling 
Since the discovery of multiple pathways activating downstream of the stimulated receptor, the 
term biased agonism was introduced [249]. The concept of biased agonism expanded 
particularly after the discovery of β-arrestin induced signaling of GPCRs [226, 250]. This 
concept defines the ability of the ligand to induce and/or receptor to acquire conformation, 
causing activation of only specific pathways downstream of that receptor [189, 190, 251, 252]. 
Various ligands have been described that specifically inhibit the G protein while activating the 
β-arrestin mediated signaling pathways or vice versa [253]. The possibility to activate specific 
pathways could be widely applied in the drug discovery field in order to minimize side effects 
[254]. 
IGF-1R as a GPCR 
IGF-1R: G protein  
It has been demonstrated that various RTKs including the IR, IGF-1R, EGFR, PDGFR and 
TrkA can utilize G-proteins for the activation of their signaling [255-261].   
It was shown that IGF-1R also couples to Gαi subunit activating MAPK pathway that can be 
blocked by compounds inhibiting G-proteins [262, 263]. In a basal state, Gαi and Gβγ both 
associate with IGF-1R [264]. IGF-1 stimulation releases Gβγ subunit but increases the 
association of IGF-1R with the Gαi subunit, thus also utilizing G proteins signaling [264]. 
Importantly, IGF-1R induced G-protein activation can result from direct IGF-1R/G-protein 
interaction as well as through transactivation of GPCRs [262, 264-266]. 
IGF-1R: GRKs  
Involvement of GRKs in desensitization of various RTKs was also reported [258, 259]. 
Activation of EGFR, PDGFR and TrkA were shown to translocate GRK2 to the plasma 
membrane resulting in activation of MAPK pathway [258, 267, 268]. 
Activated IGF-1R recruits GRKs that phosphorylate serine residues at its C-terminus [269]. 
There is a contrasting effect between GRK2 and GRK6 on IGF-1R function [269]. Both GRKs 
interact with IGF-1R, however GRK2 phosphorylates IGF-1R serine residue 1248 and induces 
transient β-arrestin 1/IGF-1R binding, while GRK6 phosphorylates serine residue 1291, 
inducing stable interaction of β-arrestin 1 with IGF-1R [269].  
IGF-1R: β-arrestins  
Both β-arrestin isoforms were shown to interact with the IGF-1R [264, 270, 271]. It has also 
been demonstrated that β-arrestin 1 interacts with the C-terminus of IGF-1R transiently binding 
to serine residue 1248 and stably binding to serine residue 1291 whereas the site of β-arrestin 2 
interactions with IGF-1R has not yet been described [272, 273]. 
IGF-1R tyrosine kinase inactivation (“desensitization”) 
One described mechanism of termination of IGF-1R TK signaling is the dissociation of IRS-1 
from the receptor followed by Mdm2 dependent ubiquitination and degradation of IRS-1 [274]. 
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It was shown that β-arrestin 1 competes with IRS-1 for Mdm2 binding and IGF-1/insulin 
treatment downregulate β-arrestin 1 thus enhancing IRS-1/2 degradation and signal cessation 
[274-278]. On the other hand, β-arrestin 1 is directly involved in IGF-1R degradation thus also 
contributes to the TK signaling cessation [272]. 
IGF-1R trafficking 
The role of the β-arrestin system in the downregulation of IGF-1R and other RTKs such as 
EGFR, PDGFR and IGF-1R has been reported [257, 272, 279]. β-arrestin 1 is recruited to the 
EGFR upon ligand stimulation, inducing receptor endocytosis [264, 277, 279]. Residues 319-
418 of the C terminus of β-arrestin 1 are involved in EGFR/β-arrestin 1 interaction with 
clathrin, indicating the importance of β-arrestin 1 dephosphorylation [264, 277, 279]. β-arrestin 
1 also mediates interaction of PDGFβ with the GPCR EDG1 leading to internalization of 
PDGFR/EDG1 complex through clathrin-coated pits [257, 280]. Ligand binding to TrkA also 
recruits β-arrestin 1 to the receptor leading to the clathrin mediated receptor endocytosis [258, 
281]. It has been suggested that TrkA/β-arrestin 1 association is also mediated through GPCR 
EDG2 [258, 281]. However, the role of the β-arrestin 2 isoform in RTK internalization and 
signaling is mostly unexplored.  
It is demonstrated that clathrin dependent internalization of IGF-1R is mediated by both β-
arrestin isoforms [270]. Dephosphorylation of C-terminal serine 412 residue of β-arrestin 1 is a 
prerequisite for this internalization [270]. The ubiquitin ligase Mdm2 is recruited to activated 
IGF-1R through β-arrestin 1 leading to receptor degradation [273, 282]. Both β-arrestin 
isoforms were shown to induce IGF-1R ubiquitination and downregulation with β-arrestin 1 
being more potent than β-arrestin 2 [272]. The mechanism and biological outcomes of this 
difference have not yet been investigated. 
IGF-1R and β-arrestin induced signaling (TK independent signaling) 
Despite indication of β-arrestin 1 involvement in ligand-induced EGFR downregulation, no 
studies have shown the effect of β-arrestins on EGFR mediated MAPK signaling [264, 277, 
279, 283]. However, it has been shown that PGE2 induced EGFR transactivation followed by 
Akt signaling is mediated through β-arrestin 1 [284]. It has been demonstrated that ligand 
binding to TrkA recruits β-arrestin 1 thus mediating activation of MAPK signaling [281]. The 
specific role of β-arrestin isoforms on PDGF and FGFR signaling remains unknown [257, 280]. 
Ligand dependent interaction of IR with β-arrestin 2 was shown to activate Akt through Src 
thus contributing to insulin PI3K signaling [285]. β-arrestin 1 was not shown to affect insulin 
induced metabolic or mitogenic signaling pathways of IR [264, 274-277]. 
Recruitment of β-arrestin 1 to IGF-1R has been shown to mediate IGF-1 induced activation of 
MAPK and PI3K signaling [264, 270, 271, 286]. Activation of MAPK requires β-arrestin 1 
dephosphorylation, its association with clathrin as well as recruitment of Mdm2 [270, 282]. The 
mechanism of IGF-1R/β-arrestin 1 mediated PI3K activation is not fully investigated [286].  
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IGF-1R: biased signaling 
Since the discovery of the GPCR properties of RTKs, the paradigm of biased agonism was also 
introduced to the field of RTKs [287-289]. 
Different extracellular domains of RTKs responsible for activation of distinct signaling 
pathways have been identified [290-296]. Various alterations of ligands, presence of co-
receptors and certain intracellular proteins were shown to induce allosteric modulations of 
RTKs [297-301]. For instance, PKCε was shown to interact with the cytosolic domain of EGFR 
inhibiting PLCγ but not ERK and Akt signaling and altering sensitivity to EGFR inhibitors 
[297, 298]. All these studies offer new possibilities to target RTKs with various biased agonists 
for better therapeutic outcomes [292-296]. 
A limited number of biased agonists have been described for RTKs [287]. It has been 
demonstrated that a specific inhibitor of FGFR, SSR128129E, binds to the extracellular domain 
of the receptor changing its conformation and inhibiting MAPK but not phospholipase C 
activation [302, 303]. A compound interacting with the juxtamembrane domain of TrkA was 
shown to inhibit receptor inducing its dimerization and biased signaling [304]. 
Biased signaling of IGF-1R was first described when the kinase inhibitor cyclolignan 
picropodophyllin (PPP) was shown to induce IGF-1R downregulation and biased ERK 
signaling [305]. Similarly, the antimicrobial peptide LL-37 has been demonstrated to induce 
IGF-1R degradation with activation of biased signaling [306]. The IGF-1R antibody 
figitumumab (CP-751871 or CP), previously described as a receptor antagonist also maintains 
agonist like properties, it induces IGF-1R downregulation and activates β-arrestin 1-dependent 
ERK signaling [307]. Since the discovery of these properties, it becomes important to test the 
effect of all IGF-1R targeting molecules on all pathways downstream of IGF-1R. 
To sum up, all main characteristics of GPCR activation and desensitization were detected at the 
IGF-1R: 1) IGF-1 binding activates the G protein signaling cascade, as well as the classical 
tyrosine kinase signaling [264]; 2) IGF-1R phosphorylation by GRK2 or GRK6 at C-terminal 
serine residues allows β-arrestin binding to the receptor [269]; 3) the GRK phosphorylated 
receptor undergoes ubiquitination and degradation or recycling to the cell surface [269, 272]; 4) 
β-arrestin recruitment leads to cessation of IGF-1R signaling [272]; 5) β-arrestin binding 
activates a second wave of IGF-1R signaling called β-arrestin dependent signaling [282]; 6) 
IGF-1R targeting molecules can be classified based on their biased agonistic properties [88]. 
Thus it has been proposed to classify the IGF-1R as a functional hybrid of both RTK and 
GPCR [88]. 
Simplified overview of the previously known roles for β-arrestins in IGF-1R activation and 
signaling is provided in Figure 3. 
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β-arrestins and cancer 
β-arrestin signaling of GPCRs and RTKs regulates multiple cancer inducing cellular functions 
such as cell proliferation, migration, invasion, anti-apoptotic signaling and cell cycle 
progression [218, 222, 224, 226, 234, 236, 284, 308-314]. β-arrestins activate these functions 
by scaffolding various cytosolic proteins as well as directly regulating expression of genes 
[218, 224, 226, 234, 237, 315, 316]. Both β-arrestins are involved in different cancer related 
receptor functions [236, 314]. 
Overexpression of β-arrestin 1 in transgenic mice increases VEGF induced MMP-9 activity and 
cell growth [317]. Stimulation of various GPCRs (FPR1, AT1R, V2R, and CXCR2) induces 
apoptosis in β-arrestins 1 and 2 knockout mouse embryonic fibroblasts (MEFs) while 
expression of β-arrestins rescues this effect [309]. 
β-arrestins mediate neurokinin-1 receptor (NK1R) induced ERK activation through Src, leading 
to cell proliferation and anti-apoptosis [318]. IGF-1 activation causes a β-arrestin 1 mediated 
increase of pERK1/2 and pAkt leading to cell proliferation and anti-apoptosis [282, 286]. The 
C-terminal domain of β-arrestin 2 plays specific role in anti-apoptotic signaling through adaptor 
protein AP2 [319, 320]. β-arrestin 2 mediates AT1R induced anti-apoptotic signaling through 
MAPK and PI3K pathway by phosphorylation of apoptotic protein BAD [321]. β-arrestin 2 
also attenuates GSK-3β apoptotic signaling of Toll-like receptor 4 [322]. Similarly, β-arrestin 2 
inhibits resveratrol induced GSK-3β mediated apoptosis of endometrial cancer cells [323]. 
CXCR4 induced cell migration is mediated by β-arrestin 2 activated MAPK pathways [324, 
325]. However, β2AR induced dephosphorylation of β-arrestin 2 promotes apoptosis after UV 
exposure via stabilization of IκBα/NF-κB association [326]. In addition, activated δ opioid 
receptor (DOR) recruits Mdm2 through β-arrestin 2 thus inhibiting Mdm2/p53 interaction and 
increasing p53-mediated apoptosis [327]. 
Figure 3. a) Absence of the ligand determines absence of the TK activity as well as IGF-1R/β-
arrestin interaction and β-arrestin signaling; b) IGF-1 binding leads to TK activation, followed 
by GRK phosphorylation and recruitment of β-arrestin 1 and Mdm2 leading to receptor 
degradation and ERK signaling; c) CP binding inhibits the TK activity of the receptor but 
recruits β-arrestin 1 leading to receptor degradation and ERK signaling. 
IRS 
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Specific involvement of β-arrestin isoforms in various types of cancer summarized in Table 3. 
 
1.4. Tumor suppressor p53 pathway 
The p53 pathway is a crucial tumor suppressor pathway that is probably inactivated in all 
tumors [18, 350-352]. p53 prevents cancer by maintaining genetic stability in damaged cells 
and eliminating incipient tumor cells [353, 354]. Oncogenic stress induces p53 phosphorylation 
and acetylation, which inhibits its interaction with the Mdm2 ubiquitin ligase and thereby 
stabilizes p53, and activates p53 as a transcription factor [353-357]. Activated p53 
transcriptionally activates target genes and induces growth arrest and if necessary, apoptosis or 
senescence [353-356]. In an unstressed environment p53 is degraded and kept at low levels by 
Cancer Isoform Mechanism of involvement Ref. 
Colon 
cancer 
β-arrestin 1 Mediates PGE2 induced EGFR transactivation [284] 
β-arrestin 2 Mediates Wnt signaling [313] 
Bladder 
cancer 
β-arrestin 1 Not involved in TPβR induced malignancy [328] 
β-arrestin 2 Mediates TPβR signaling [329] 
Blood 
cancers 
β-arrestin 1 Elevated in ALL, inhibits Notch1 signaling [330] 
β-arrestin 2 Involved in CML, mediates Wnt signaling [310] 
Prostate 
cancer 
β-arrestin 1 Mediates Wnt signaling [331] 
β-arrestin 2 
Downregulates AR and TβRIII; Mediates β2AR induced 
c-Src activation 
[332-
335] 
Pancreatic 
cancer 
β-arrestin 1 N/D  
β-arrestin 2 
Mediates CXCR4/7 induced MAPK signaling; 
Possibly mediates increased Shh signaling 
[336-
339] 
Brain 
tumors 
β-arrestin 1 Low phospho-S412 correlated with low survival in GBM [340] 
β-arrestin 2 Possibly mediates increased CXCR4 signaling in MBM [341] 
NSCLC 
β-arrestin 1 
Mediates PGE2 induced EGFR transactivation and 
nAChRs signaling; Nuclear increase correlates with 
poor prognosis 
[308, 
342, 
343] 
β-arrestin 2 Decrease correlates with poor prognosis [312] 
Breast 
cancer 
β-arrestin 1 
Mediate LPAR and PAR2 signaling and HIF-1α 
dependent activation of VEGF-A; Decreased with tumor 
progression, correlating with poor prognosis 
[222, 
344-
346] 
β-arrestin 2 
Mediate LPAR, PAR2 and KISS1R signaling; TβRIII 
dependent inhibition of NF-κB; Possibly mediates 
CXCR4 signaling; Increased with tumor progression, 
correlating with poor prognosis 
[222, 
344, 
346-
349] 
Ovarian 
cancer 
β-arrestin 1 Mediates ETAR signaling and EGFR transactivation [311] 
β-arrestin 2 Mediates ETAR signaling and EGFR transactivation [311] 
Table 3. Mechanisms of β-arrestin 1 and 2 involvement in various types of cancer. 
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Mdm2 that binds to p53, mono-ubiquitinates it and exports to the cytosol where p53 is 
degraded in the proteasome [353-356]. Expression of Mdm2 is also transcriptionally regulated 
by p53 through a negative feedback loop [353-357]. 
The TP53 gene is mutated in around 50% of cancers [358, 359]. Most TP53 mutations are 
missense mutations that disrupt p53 DNA binding [358, 359]. Mutant p53 can exert a dominant 
negative effect on a wild type p53 [358, 359]. Another mechanism of p53 inactivation is 
overexpression of its natural inhibitor, the E3 ubiquitin ligase Mdm2, in cancer cells [358-361]. 
1.5. Link between IGF-1R signaling and p53 pathway 
There is a solid amount of data indicating that p53 interacts with the IGF-1 pathway 1) at the 
transcriptional level; 2) through regulation of metabolic processes; 3) and through convergence 
of the IGF-1R and p53 signaling pathways [362, 363]. 
Link at the transcriptional level 
It has been shown that wild type p53 suppresses transcription of IGF-1R, possibly as part of its 
apoptotic effect, however mutant p53 activates IGF-1R expression [364-366]. Wild type p53 
also inhibits transcription of IGF-2 and induces transcription of the IGFBP2 and IGFBP3 genes 
[367-369]. In addition, p53 homologs p63 and p73 proteins also inhibit IGF-1R transcription 
while their mutant forms fail to do so [370]. Other tumor suppressors such as BRCA1, pVHL 
and WT1 were also demonstrated to reduce expression of IGF-1R [371-374]. 
Regulation of metabolic processes 
The interplay between IGF-1R and the p53 pathway is also implicated in regulation of 
metabolic pathways [375]. IGF-1 directly regulates glucose uptake and inhibits hepatic 
production of glucose [376]. However, wild type p53 inhibits glycolysis through repression of 
GLUT1 and GLUT4 genes, while mutant p53 lacks this function [377]. Wild type p53 also 
promotes hepatic production of glucose thus possibly preventing glycolysis utilized by cancer 
cells [378]. Another example is that IGF-1 stimulates expression of the transcription factor 
SREBP involved in sterol synthesis, while p53 inhibits SREBP and thus lipogenesis [379, 380]. 
Convergence of signaling pathways 
Mdm2 is a well-described ubiquitin ligase for both p53 and IGF-1R [273, 381]. It was 
demonstrated that IGF-1 signaling affects the activity of Mdm2 towards p53 [382, 383]. IGF-
1R activation induces PI3K pathway leading to Akt translocation to the nucleus followed by 
up-regulation of transcription factors involved in cell growth and anti-apoptosis [382, 383]. 
However, Akt also phosphorylates Mdm2 inhibiting its association with predominantly nuclear 
protein ARF [382-384]. This leads to nuclear export of the Mdm2/p53 complex followed by 
cytoplasmic proteasomal degradation of p53 [383-386]. p53 can inhibit the PI3K pathway 
through activation of the inhibitor of this pathway, PTEN [387].  
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It was also shown that IGF-1 induces Mdm2-dependent p53 degradation in response to DNA 
damage through activation of MAPK pathway [384, 388-390]. In addition p53 can inhibit 
MAPK pathway through caspase-mediated cleavage of the ERK2 [391]. 
β-arrestin 1 was shown to mediate Mdm-2 dependent IGF-1R degradation and MAPK 
signaling [272, 282]. Interestingly β-arrestin 1 also facilitates Akt induced p53 degradation by 
Mdm2 downstream of β2AR [392]. However, the role of β-arrestins in IGF-1 induced 
Mdm2/p53 interaction has not been elucidated. 
Thus IGF-1R and p53 pathway are interconnected at multiple levels and dissection of this 
complex interplay has a major impact on understanding of basic physiology as well as on 
improvement of specific anti-cancer therapies. 
A simplified scheme of IGF-1R interplay with the p53 pathway is provided in Figure 4.  
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Figure 4. Schematic illustration of interplay between IGF-1R and wild type (green) and mutant 
(grey) p53. Dashed line indicates transcriptional regulation, solid line indicates regulation at 
the protein level. Arrowed lines indicate stimulatory and blunted lines indicate inhibitory 
effects. 
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2. AIM OF THE THESIS 
The main aim of this thesis was to investigate in detail the IGF-1R/β-arrestin/Mdm2/p53 axis in 
cancer and to explore the potential use of its components as therapeutic targets. 
Paper I: To analyze the molecular interplay between p53 and IGF-1R pathways through Mdm2. 
Paper II: To investigate the role of β-arrestin isoforms in the IGF-1R/β-arrestin/Mdm2/p53 
axis. 
Paper III: To reveal a potential of co-targeting the IGF-1R/β-arrestin/Mdm2/p53 axis with the 
MAPK pathway. 
Paper IV: To reveal the potential of co-targeting the IGF-1R/β-arrestin/Mdm2/p53 axis with 
DNA damage inducing drugs. 
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3. RESULTS AND CONCLUSIONS 
3.1. Paper I: Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-
1-dependent invasive phenotype of skin melanoma 
Background and rationale: 
p53 mutations are rare in melanoma and instead p53 is often inhibited by up-regulation of the 
ubiquitin ligase Mdm2 [393-396]. Thus, the disruption of the Mdm2/p53 interaction could be a 
rational approach for melanoma treatment. The IGF-1R is another important player in 
melanoma cell survival and is also regulated by ubiquitin ligase Mdm2 [273, 397, 398]. As 
both p53 and IGF-1R are substrates of Mdm2, we investigated the impact of Mdm2/p53 
disruption on function of IGF-1R in a melanoma model. 
Results and conclusions: 
We used the prototypical p53-reactivator Nutlin-3 to disrupt Mdm2/p53 complex in four 
melanoma cell lines, two with wild type (wtp53) and two with mutant p53 (mtp53). 
Since Mdm2 is a ubiquitin ligase for IGF-1R, we first investigated the effect of Nutlin-3 on the 
levels of Mdm2 and IGF-1R. We demonstrated that in wtp53 cells, Nutlin-3 causes a dose and 
time dependent accumulation of p53 and Mdm2, accompanied by a decrease in the level of 
IGF-1R. No significant effects on the level of p53, Mdm2 or IGF-1R were observed in mtp53 
cells. These data indicate that Nutlin-3 affects IGF-1R level following increase of Mdm2. 
It has been demonstrated that Mdm2 induces IGF-1R ubiquitination followed by its 
degradation and pERK signaling in response to IGF-1 stimulation [272, 273, 282]. Thus, we 
next tested whether IGF-1 stimulation was essential for the Nutlin-3 mediated IGF-1R 
degradation. Cells were Nutlin-3 treated, serum starved, IGF-1 stimulated and monitored for 
changes in the level of IGF-1R using western blot (WB). We demonstrated that IGF-1R 
degradation only occurred in the presence of IGF-1, despite similar levels of p53 accumulation 
in both serum free and IGF-1 conditions. This effect was also obvious only in wtp53 cells. 
We next investigated the mechanism of Nutlin-3 dependent IGF-1R downregulation. Using 
qPCR we excluded transcriptional origin of Nutlin-3 mediated IGF-1R decrease. Using 
immunoprecipitation (IP) we investigated whether IGF-1R is physically associated with and 
ubiquitinated by Mdm2 after Nutlin-3 treatment. In serum starved conditions recruitment of 
Mdm2 to the IGF-1R was very low, increasing after Nutlin-3 treatment or IGF-1 stimulation 
and reaching maximum after Nutlin-3 treatment followed by IGF-1 stimulation. A similar 
pattern was observed for ubiquitination level: Nutlin-3 or IGF-1 treatment alone increased IGF-
1R ubiquitination, while double treatment increased it further. We next tested Nutlin-3 induced 
IGF-1R degradation in cells expressing low level of Mdm2 (SAOS) and full length (MEF wt) 
and C-terminus truncated (Δ1245) IGF-1R. In SAOS2 cells Nutlin-3 treatment did not induce 
either p53 or Mdm2 accumulation, while in MEF wt and Δ1245 it induced both. However, 
Nutlin-3 induced IGF-1R degradation was only observed in MEF wt cells. These data 
confirmed that Mdm2-mediated ubiquitination of the IGF-1R is a key mechanism of Nutlin-3 
induced IGF-1R downregulation. 
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Since IGF-1R ubiquitination by Mdm2 also activates pERK we next tested the effect Nutlin-3 
may have on IGF-1R signaling. We stimulated untreated and Nutlin-3 treated cells with IGF-1 
for up to 60 minutes and observed an early and overall increase of pERK in Nutlin-3 treated 
samples, compared to untreated. This increase was eliminated by IGF-1R downregulation and 
was not observed in SAOS-2 and Δ1245 cells. These results demonstrated that Nutlin-3 acts as 
a partial agonist for IGF-1R induced pERK signaling through Mdm2. 
IGF-1R is a potent inducer of cell transformation, proliferation, invasion and metastasis [117, 
148, 399]. Thus, we next investigated the effect of Nutlin-3 on these biological behaviours. 
Using a soft agar assay, cell viability assay and FACS analysis we demonstrated that Nutlin-3 
treatment inhibits colony formation, slightly increases total cell number, and decreases overall 
IGF-1 response. Using both monolayer wound healing and transwell chamber assays we 
demonstrated that Nutlin-3 increased at early stage and decreased at later time points IGF-1 
induced migration, particularly in wtp53 cells. However, a matrigel invasion assay and 
monitoring of MMP-2 activation showed that Nutlin-3 completely inhibits IGF-1 induced 
invasion. To sum up, Nutlin-3 inhibits IGF-1R induced cell proliferation/survival, has a two-
step effect on IGF-1 induced cell migration and completely abolishes IGF-1 induced invasion. 
The main findings of the study are that 1) p53/Mdm2 disruption activates IGF-1R interaction 
with Mdm2; 1) Nutlin-3 comprises agonistic properties towards IGF-1R induced pERK; 2) 
p53/Mdm2/IGF-1R axis could be used as a potential target for anti-cancer therapy. 
 
 
 
 
 
Figure 5. Schematic illustration of the p53/Mdm2/IGF-1R axis in the a) absence of Nutlin-3 
and IGF-1; b) presence of Nutlin-3; c) presence of both, Nutlin-3 and IGF-1. 
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3.2. Paper II: Functional antagonism of β-arrestin isoforms balance IGF-1R expression 
and signaling with distinct cancer-related biological outcomes 
Background and rationale: 
The roles of the two β-arrestins (β-arrs) with similar structure are well characterized in various 
GPCRs [224, 226]. In regards to their function at the IGF-1R, it is mainly the function of β-arr1 
that has been described so far. It has been demonstrated that β-arr1 induces ligand dependent 
IGF-1R degradation, activates late MAPK signaling, and is able to mediate resistance to IGF-
1R targeting in cancer [272, 282, 305]. However, it was also shown that both β-arrs can bind 
and ubiquitinate the IGF-1R leading to its degradation [269, 272]. Yet little is known about the 
specific function of β-arr2 on IGF-1R expression and function. In this study, we particularly 
focused on the role of the β-arr2 isoform and identified distinct roles for the two isoforms on 
IGF-1R system as well as on the interconnected p53 pathway. 
Results and conclusion: 
It has been shown that β-arr isoforms can differently downregulate various GPCRs [219, 225, 
227]. Thus, we first studied the effect of β-arr2 on IGF-1R expression. β-arr1 knock out 
(β1KO), β-arr2 knock out (β2KO) and wild type (WT) MEF cells were serum starved and 
stimulated with IGF-1 for 0, 12 and 24 h followed by monitoring of IGF-1R degradation rate 
by WB. Our results indicated that IGF-1R degradation is impaired in β1KO, and enhanced in 
β2KO cells compared to WT cells. We next transfected HEK and WT MEF cells with β-arr1 or 
β-arr2 encoding plasmids or siRNAs and showed that β-arr1 up-regulation and β-arr2 inhibition 
enhances, whilst β-arr1 inhibition and β-arr2 up-regulation impairs IGF-1R degradation. 
Importantly, IGF-1R level was decreased in serum starved β-arr2 up-regulated cells prior to 
stimulation. This experiment demonstrated that in contrast to β-arr1, β-arr2 inhibits the rate of 
ligand dependent degradation of IGF-1R. 
It has been also demonstrated that β-arr1 sustains IGF-1 induced ERK activation [282]. 
Therefore, we next tested the effect of β-arr2 on modulation of IGF-1R signaling. We serum 
starved and stimulated β1KO, β2KO and WT MEF cells with IGF-1 for 0, 2, 5, 10, 30 and 60 
minutes and indicated that ERK activation lasts longer in β2KO and shorter in β1KO 
compared to WT cells. Down- or upregulation of β-arr2 in HEK and MEF cells confirmed that 
β-arr2 inhibition prolongs and up-regulation shortens IGF-1 activated ERK. These data indicate 
opposing roles for β-arr1 and β-arr2 on IGF-1-induced late ERK activation. 
β-arr1 is known to control IGF-1R degradation and signaling through Mdm2 dependent 
ubiquitination of the C-terminus of IGF-1R [282]. Thus, we next tested impact of Mdm2 on β-
arr2 activity by altering β-arrs in MEF cells, expressing a C-terminus truncated IGF-1R 
(Δ1245), SAOS-2 cells with low endogenous and U2OS cells with high endogenous level of 
Mdm2. We observed a similar effect for β-arr2 only in U2OS cells, while in Δ1245 and SAOS-
2 cells IGF-1R degradation and signaling was unchanged after β-arr2 alteration. This data 
indicated a role for Mdm2 and the C terminus of IGF-1R in the modulation of IGF-1R function 
by β-arr2. 
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We next tested whether β-arr2 also binds to and induces ubiquitination of the IGF-1R. We up-
regulated IGF-1R and either β-arr1 or β-arr2 in U2OS cells, followed by serum starvation, IGF-
1 stimulation and immunoprecipitation of the β-arrs. We analyzed the immunoprecipitates and 
demonstrated that β-arr2 preferentially binds to and induces ubiquitination of a ligand-free IGF-
1R, while β-arr1 - of a ligand occupied IGF-1R. 
Next, we assessed the biological outcomes of modulation of IGF-1R expression and ERK 
activation by β-arr isoforms. We modulated β-arr1 or 2 in U2OS and SAOS-2 cells, followed 
by serum starvation, IGF-1 stimulation and analysis of proliferation/survival and cell cycle 
distribution using PrestoBlue and FACS. We revealed increased total cell number and cell 
cycle progression in response to IGF-1 after β-arr1 up-regulation and β-arr2 inhibition in both 
cell lines. β-arr2 up-regulation and β-arr1 inhibition in contrast, reduced cell number as well as 
IGF-1 response causing cell cycle arrest. Interestingly, SAOS-2 were affected more and 
arrested in G2 phase, while U2OS cells were arrested in both G1 and G2 phases, suggesting 
that p53 absence facilitates a G1/S transition even without sustained proliferative signals. 
We proposed that β-arr2 predominance decreases cell viability through β-arr2 mediated 
downregulation of IGF-1R during serum starvation and an activated p53 pathway. We 
confirmed both scenarios by monitoring a gradual decrease in IGF-1R level in serum free 
conditions and re-activation of p53 in β-arr2 up-regulated and β-arr1 inhibited cells. Thus both 
receptor depletion and increased p53 contributes to IGF-1 insensitivity in β-arr2 predominant 
conditions. 
The main findings of this study are 1) opposing roles of β-arr isoforms in modulating IGF-1R 
function; 2) an important role of β-arr1/2 balance in cell cycle progression; 3) identification of 
anti-cancer therapeutic potential of β-arr1/2 system with an impact on both pro-oncogenic IGF-
1R signaling and tumor suppressor p53 pathway. 
 
 
 
 
 
 
 
 
  
Figure 6. Schematic illustration of prevailing manner of β-arr1 or β-arr2 interaction with p53 
and IGF-1R in the a) presence of IGF-1; b) absence of IGF-1 ligand. 
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3.3. Paper III: Enhanced response of melanoma cells to MEK inhibitors following 
unbiased IGF-1R down-regulation 
Background and rationale: 
Due to frequent mutation of RAF or RAS genes, inhibition of the downstream MAPK is a 
rational approach for melanoma treatment [400]. However, current MAPK inhibitors develop 
rapid resistance soon after administration that is associated with a more aggressive disease 
recurrence [401-403]. Melanoma cells acquire alternative routes to sustain proliferative 
signaling, including IGF-1R exploitation. Thus, co-targeting of MAPK inhibition with IGF-
1R downregulation is a reasonable strategy for better outcome of treatment [404-406]. Yet 
IGF-1R downregulation can be associated with inappropriate activation of β-arr induced 
biased MAPK signaling [289, 305, 307, 407, 408]. In this study, we explore co-targeting of 
MAPK inhibition with balanced and β-arr signaling biased IGF-1R downregulation to aim to 
maximize drug sensitivity of melanoma cells. 
Results and conclusion: 
Since RAS and RAF mutations occur in high percentage in melanoma we first tested RAS/RAF 
status and sensitivity to MEK1/2 inhibitor U0126 in a panel of melanoma cell lines. We 
confirmed by sequencing that DFB and Mel28 cells contains BRAF mutation, while BE 
contains an NRAS mutation. Cells cultured in media with and without serum followed by WB 
analysis indicated that the highest level of basal pERK1/2 was in Mel28 and lowest in BE cells, 
which further increased with serum. We demonstrated a U0126 dose-dependent decrease in cell 
viability with a higher response in BRAF positive cells. We also demonstrated a higher 
sensitivity to U0126 in the absence of serum compared to presence of serum or IGF-1. Taken 
together, this data revealed that U0126 treatment decreased cell number in all cell lines and this 
effect was limited in the presence of IGF-1. 
Since IGF-1R signaling is able to decrease U0126 sensitivity we next tested various strategies 
to down-regulate IGF-1R. As a first strategy we used siRNA mediated balanced IGF-1R 
downregulation that does not modify IGF-1R signaling [409, 410]. As a second strategy we 
downregulated IGF-1R with targeted antibodies (CP), inducing biased sustained β-arr mediated 
MAPK signaling [307]. The third strategy was to downregulate IGF-1R by Nutlin-3, inducing 
biased transient β-arr mediated MAPK signaling [411]. We identified that siRNA and CP 
downregulates IGF-1R in all cell lines while Nutlin-3 has effects only in DFB and to a lesser 
extent in BE cells. Only Nutlin-3 treated DFB cells indicated p53 re-activation. We tested the 
effect of treatments on IGF-1 induced proliferation of cells. We identified a decreased IGF-1 
response in all siRNA, CP and Nutlin-3 treated DFB and to a lesser extend BE cells, whereas 
Mel28 were not affected. These results confirmed downregulation of IGF-1R and inhibition of 
IGF-1 response by three different strategies. 
We have previously demonstrated that CP and Nutlin-3 are able to activate sustained or 
transient biased ERK activation [307, 411]. Therefore, we next tested the biased agonistic 
features of all three strategies. We treated cells with CP, Nutlin-3 and siRNAs, serum starved 
them and stimulated with IGF-1 for up to 60 minutes. WB analysis revealed the following 
patterns of pERK activation: in siRNA treated cells pERK1/2 was consistently decreased in all 
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cell lines compared to untreated controls; Nutlin-3 treatment induced an early increase and late 
decrease in the level of pERK1/2 in DFB and BE cells, compared to untreated controls; CP 
treatment decreased overall but sustained late pERK1/2 in all cell lines compared to untreated 
controls. These results indicated that all strategies decreased IGF-1R signaling, however siRNA 
treatment caused a balanced decrease, while Nutlin-3 and CP treatment induced biased 
transient and sustained pERK1/2, respectively. 
We next investigated the effects of transient versus biased IGF-1R down-regulation on 
melanoma response to MEK1/2 inhibitor. Cells were first treated with siRNA, Nutlin-3 or CP, 
then with or without U0126. Results indicated a decrease in the level of IGF-1R in all cells 
except for Nutlin-3 treated Mel28 and an increase of p53 level only in Nutlin-3 treated DFB 
cells. The level of pERK was lowered in siRNA or Nutlin-3 combined with U0126 treated 
cells, but remained higher in CP combined with U0126 treated cells compared to control. 
Analysis for the total cell number indicated a 5-20% decrease after all three types of treatment. 
These data were combined with identical conditions of U0126 treatment alone to calculate a 
predicted additive response and compared with the observed response of combined treatment. 
We observed higher than predicted sensitivity to U0126 in all cells pre-treated with siRNA and 
in DFB and BE cells pre-treated with Nutlin-3, and close to predicted sensitivity to U0126 in 
cells pre-treated with CP. These data indicated synergy of balanced and transiently biased but 
not the sustained biased approach with MEK1/2 inhibition. 
The main findings of this study are: 1) IGF-1R downregulation can be balanced or 
accompanied with transient or sustained biased signaling; 2) both balanced and transient biased 
IGF-1R downregulation synergizes with inhibition of MEK1/2, while sustained biased IGF-1R 
downregulation does not; 3) Nutlin-3 treatment offers a possible strategy to increase specificity 
of combined treatment. 
 
Figure 7. Schematic illustration of IGF-1R and p53 activity after treatment with a) siRNAs 
against IGF-1R; b) p53 re-activator Nutlin-3; c) IGF-1R antibody CP 
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3.4. Paper IV: Competing engagement of β-arrestin isoforms balance IGF-1R signaling 
and control response of melanoma cells to chemotherapy 
Background and rationale: 
Dacarbazine (DTIC) is a chemotherapeutic agent that induces DNA damage leading to 
activation of p53 pathway, followed by apoptosis and cell cycle arrest. Despite poor response 
and due to lack of alternatives it remains the main compound used for the treatment of 
metastatic melanoma. The IGF-1R is an important growth factor receptor involved in 
proliferation and invasion of melanoma cells [133, 397-399]. It been demonstrated recently that 
β-arrs control both mitogenic IGF-1R signaling and the tumor suppressor p53 pathway [272, 
282, 392, 412]. In this study we aimed to investigate the possibility of co-targeting components 
of β-arr system in order to increase sensitivity to DTIC. 
Conclusion and results: 
We have demonstrated previously that β-arr isoforms play opposing roles in IGF-1 induced cell 
proliferation [412]. Thus, we first investigated the effect of β-arr modulation in melanoma cell 
lines. We first verified that all three melanoma cells express IGF-1R and the two β-arr 
isoforms. We next tested the effect of β-arr isoforms on melanoma cell proliferation and 
survival by down- and upregulating either β-arr with siRNA or β-arr encoding plasmids. We 
identified that β-arr1 silencing and β-arr2 up-regulation were most detrimental for cells and 
focused on these two conditions for further experiments. 
Since β-arr isoforms also play opposing roles on IGF-1R signaling thus we next investigated 
the effect of β-arr1 silencing and β-arr2 overexpression on receptor signaling [412]. We 
transfected DFB and BE cells with siRNA against β-arr1 or β-arr2 encoding plasmid followed 
by serum starvation and IGF-1 stimulation for 0, 2, 5, 10, 30 and 60 minutes. Using WB 
analysis, we demonstrated that in both β-arr1 silenced and β-arr2 overexpressed cells level of 
phospho-ERK decreased at 30 and 60 min after stimulation. We further investigated the effect 
of β-arr modulation on proliferative/survival response of cells to IGF-1. Cells were serum 
starved after transfection, stimulated or not with IGF-1 for 24 h, followed by cell number 
analysis. Both β-arr1 downregulation and β-arr2 up-regulation inhibited IGF-1 response by 
decreased number of cells compared to unstimulated control. These results confirmed that a β-
arr2 predominance in melanoma cells inhibits IGF-1 mediated pERK activation as well as an 
IGF-1 induced proliferative/survival response. 
β-arr isoforms were demonstrated to induce different patterns of IGF-1R ubiquitination, 
followed by its degradation or endocytosis. It was also shown that IGF-1R internalization 
through β-arr1 or β-arr2 has opposing effects on the activation of p53 pathway [272, 282, 412]. 
Therefore, we next investigated the effect of β-arr modulation on IGF-1R degradation and 
activity of p53 pathway. Using WB analysis, we identified a decreased rate of IGF-1 induced 
receptor degradation in both β-arr1 silenced and β-arr2 upregulated cells. Importantly, in both 
conditions, the level of IGF-1R was decreased at time 0 compared to mock. WB analysis of 
lysates for p53 expression indicated its upregulation in both conditions. These data 
demonstrated that β-arr2 predominance downregulates ligand-free IGF-1R, inhibits ligand 
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induced IGF-1R degradation and activates p53 in melanoma cells. 
DTIC is an alkylating agent that induces DNA damage causing cell cycle arrest and inhibition 
of melanoma cell growth [413].  Thus, we next tested the effect of DTIC as a single agent in 
BE, DFB and Mel28 melanoma cell lines. Cells were treated for 24 and 48 h with various doses 
of DTIC in media with or without serum or IGF-1. Using PrestoBlue we demonstrated 
decreased cell viability and in all cell lines. WB analysis of samples treated with different doses 
of DTIC for 24 h indicated an increase in the level of p53. DFB cells were more sensitive to 
DTIC and demonstrated a higher reactivation of p53 than in BE and Mel28 cells. These data 
confirmed the effect of DTIC on melanoma cells. 
Since we demonstrated a negative effect of β-arr2 predominance on cell proliferation, we next 
tested if this can increase the sensitivity of melanoma cells to DTIC. We compared the effect of 
single and combined treatments of DTIC with β-arr1 silencing and β-arr2 overexpression. We 
calculated a predicted response to combined treatment by addition of two single agent 
sensitivity data. We observed a synergistic effect of combined treatments in all cell lines, 
indicating that β-arr2 predominance potentiates the DNA damage induced by DTIC in 
melanoma cells. 
The main outcomes of this study are that 1) β-arr2 predominance positively affects p53 
activation and negatively affects ligand induced IGF-1R degradation, MAPK activation and 
proliferation and survival in melanoma cells; 2) β-arr2 predominance synergizes with DTIC 
treatment in both mtp53 and wtp53 cells. 
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Figure 8. Schematic illustration of the combined effects of dacarbazine with β-arr2 predominance 
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4. DISCUSSION AND FUTURE PROSPECTIVES 
The starting point of this thesis was that IGF-1R signaling and p53 pathway share similar 
regulatory mechanisms: Mdm2 and βarrs. This cross-regulation between two pathways 
involved in cancer has important implications for anti-cancer therapy and needs to be fully 
understood. The overall goal of the thesis was to investigate the IGF-1R/β-arr/Mdm2/p53 axis 
in cancer and to explore the potential use of its components as therapeutic targets. 
In the first paper, we investigated the effect of destabilizing IGF-1R/Mdm2/p53 complex using 
Nutlin-3 and melanoma cells as an experimental model. In the second paper, we focused on the 
β-arr component of this axis and exploited the possibility to target these components in 
melanoma. In the third and fourth papers, we tried to exploit different approaches to target the 
IGF-1R/β-arr/Mdm2/p53 axis. In the third paper, we investigate the effect of co-targeting IGF-
1R with MEK pathway, and in the fourth paper we explore the possibility of co-targeting β-arrs 
with a DNA repair pathway. 
Our group has previously described various compounds and antibodies against IGF-1R as IGF-
1R biased agonists [305-307]. Anti-IGF-1R antibody CP induces biased pERK that contributes 
to the survival of CP-treated Ewing's sarcoma cell lines [307]. The antimicrobial peptide LL-37 
downregulates the IGF-1R whilst activating biased signaling, that contributes to breast cancer 
cells invasion and migration [306]. My studies reveal that Nutlin-3 also acts as an IGF-1R 
biased agonist, activating the MAPK pathway, that contributes to cell migration but not 
invasion. This study points out a highly specific mechanism of activation of IGF-1R biased 
signaling by various agonists, resulting in distinct biological outcomes. Characterization of the 
proteins involved in these pathways that could increase the possibility of more specific anti-
cancer targeting is one of the future prospectives of this project. The involvement of β-arr 
isoforms in this signaling deserves particular attention. It has been demonstrated that β-arr1 
mediates CP and LL-37 induced IGF-1R biased signaling [306, 307], however the role of β-arr 
isoforms in Nutlin-3 mediated ERK activation, as well as the specific role of β-arr2 in any types 
of IGF-1R signaling has not yet been identified. 
In one of the studies we particularly focused on the β-arr components of the IGF-1R/β-
arr/Mdm2/p53 axis. We revealed opposing roles of β-arr isoforms in the regulation of IGF-1R 
at multiple levels – β-arr1 induces while β-arr2 inhibits ligand-dependent IGF-1R degradation; 
β-arr1 sustains while β-arr2 shortens ERK activation; and β-arr2 activates, while β-arr1 inhibits 
p53 pathway downstream of IGF-1R activation. However, in the absence of IGF-1 both β-arrs 
downregulate IGF-1R with β-arr2 exerting a stronger effect. This points out that IGF-1R acts as 
both a Class A and Class B GPCR depending on the presence of the ligand. It seems that in the 
absence of the ligand IGF-1R preferentially and transiently recruits β-arr2, while an IGF-1 
stimulated IGF-1R stably recruits β-arr1. Another important finding is that the antagonism 
between the two β-arr isoforms could be used as a target for anti-cancer therapy. We 
demonstrated that β-arr2 predominance inhibits response to IGF-1, causes cell cycle arrest, and 
activates p53 pathway resulting in a decrease of cell viability. 
Opposing role of β-arrs at different levels of IGF-1R regulation raises the question of the reason 
for divergence of two isoforms with 78% identity and 88% similarity [414]. Possible 
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explanations include different affinity of the isoforms for distinct IGF-1R conformations, as 
well as competition for binding to the receptor and to each other [247, 392, 415, 416]. Another 
question is whether distinct agonists also induce different confirmations of IGF-1R, 
preferentially recruiting one of the isoforms. In this case biased agonists with preferential 
recruitment of β-arr2 would be favoured for anti-cancer treatment. Elucidation of the exact 
mechanism of IGF-1R interaction with β-arr isoforms is one of the future prospectives.  
Investigation of the possibility to combine IGF-1R inhibitors with MEK inhibitors indicated 
that results are critically different depending on the strategy of IGF-1R inhibition. The first 
strategy of balanced IGF-1R inhibition by siRNA greatly enhanced response to MAPK 
inhibitors. However, a second strategy using anti-IGF-1R antibody CP was less successful. We 
revealed that CP not only induces biased IGF-1R signaling, but also is able to bias the IGF-1R 
towards its ligand even after CP removal. Thus, it was not surprising that CP treatment 
demonstrated limited effects on MEK1/2 inhibition. As discussed previously, certain RTK 
antibodies can bind to the receptor’s extracellular domain without affecting receptor/ligand 
interaction [292-296]. Moreover, a specific IR antibody has been described that increases the 
binding affinity of insulin to the IR thus enhancing the receptors metabolic signaling [301]. 
This mechanism could be a possible explanation of the specific effect of CP on IGF-1R. The 
precise mechanism of CP/IGF-1R interaction remains to be investigated. A third strategy of 
IGF-1R inhibition using Nutlin-3 greatly enhanced the effect of MEK inhibitors. The transient 
character of Nutlin-3 induced biased signaling is an explanation for the better outcome. Thus, 
co-targeting MAPK pathway with IGF-1R using Nutlin-3 is the first anti-cancer strategy 
revealed in this project. 
Another study was focused on the possibility to co-target β-arr components of the axis with the 
p53 pathway. We demonstrated that both β-arr1 inhibition and β-arr2 overexpression increase 
sensitivity of melanoma cells to DNA damage inducing drug dacarbazine. This study identified 
the second rational anti-cancer strategy in this project. 
In conclusion, two successful strategies of co-targeting IGF-1R/β-arr/Mdm2/p53 axis with 
different cancer related pathways have been identified in this thesis. One strategy combines 
MEK inhibition with Nutlin-3 to greatly enhance IGF-1R degradation, transiently activate 
pERK and induce p53 re-activation. Another strategy is the combination inhibition of β-arr1 or 
activation of β-arr2 with dacarbazine treatment. This strategy, in contrast, has a moderate effect 
on IGF-1R degradation, strongly inhibits IGF-1R signaling and has double potential to activate 
p53 pathway. The synergistic effect of both strategies shows that accurate removal of multiple 
interconnected pathways of IGF-1R/β-arr/Mdm2/p53 axis can lead to an optimal context 
dependent anti-cancer effect. 
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